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Incremental Prognostic Value of Cardiac Computed
Tomography in Coronary Artery Disease Using CONFIRM
COroNary Computed Tomography Angiography Evaluation for Clinical
Outcomes: An InteRnational Multicenter Registry
Benjamin J.W. Chow, MD; Gary Small, MBBS; Yeung Yam, BSc; Li Chen, MSc;
Stephan Achenbach, MD; Mouaz Al-Mallah, MD, MSc; Daniel S. Berman, MD;
Matthew J. Budoff, MD; Filippo Cademartiri, MD, PhD; Tracy Q. Callister, MD;
Hyuk-Jae Chang, MD, PhD; Victor Cheng, MD; Kavitha M. Chinnaiyan, MD; Augustin Delago, MD;
Allison Dunning, MSc; Martin Hadamitzky, MD; Jo¨rg Hausleiter, MD; Philipp Kaufmann, MD;
Fay Lin, MD; Erica Maffei, MD; Gilbert L. Raff, MD; Leslee J. Shaw, PhD; Todd C. Villines, MD;
James K. Min, MD; on behalf/for the CONFIRM Investigators
Background—Large multicenter studies validating the prognostic value of coronary computed tomographic angiography
(CCTA) and left ventricular ejection fraction (LVEF) are lacking. We sought to confirm the independent and
incremental prognostic value of coronary artery disease (CAD) severity measured using 64-slice CCTA over LVEF and
clinical variables.
Methods and Results—A large international multicenter registry (CONFIRM Registry) was queried, and CCTA patients
with LVEF data on CCTA were screened. Patients with a history of myocardial infarction, coronary revascularization,
or cardiac transplantation were excluded. The National Cholesterol Education Program-Adult Treatment Panel III risk
was calculated for each patient, and CCTA was evaluated for CAD severity (normal, nonobstructive, non–high-risk, or
high-risk CAD) and LVEF 50%. Patients were followed for an end point of all-cause mortality; 27 125 patients
underwent CCTA at 12 participating centers, with a total of 14 064 patients meeting the analysis criteria. Follow-up was
available for 13 966 (99.3%) patients (mean follow-up of 22.5 months; 95% confidence interval, 22.3 to 22.7 months).
All-cause mortality (271 deaths) occurred in 0.65% of patients without coronary atherosclerosis, 1.99% of patients with
nonobstructive CAD, 2.90% of patients with non–high-risk CAD, and 4.95% for patients with high-risk CAD.
Multivariable analysis confirmed that LVEF 50% (hazard ratio, 2.74; 95% confidence interval, 2.12 to 3.51) and
CAD severity (hazard ratio,1.58; 95% confidence interval, 1.42 to 1.76) were predictors of all-cause mortality, and
CAD severity had incremental value over LVEF and clinical variables.
Conclusions—Our results demonstrate that CCTA measures of CAD severity and LVEF have independent prognostic
value. Incorporation of CAD severity provides incremental value for predicting all-cause death over routine clinical
predictors and LVEF in patients with suspected obstructive CAD. (Circ Cardiovasc Imaging. 2011;4:463-472.)
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Prior studies have demonstrated superior operating char-acteristics for cardiac computed tomographic angiog-
raphy (CCTA), and CCTA has had increasing acceptance
into daily clinical practice for the diagnosis of obstructive
coronary artery disease (CAD).1–5 Single-center studies
suggest that CCTA has prognostic value for both all-cause
mortality and major adverse cardiac events.6 –12 However
the validation of CCTA prognosis in large multicenter
cohorts is lacking.
Editorial see p 457
Clinical Perspective on p 472
Previously, in a single-center study, the severity of CAD
and left ventricular ejection fraction (LVEF) have been
demonstrated to predict major adverse cardiac events and
all-cause mortality.11 The objective of the present study is to
confirm the prognostic and incremental value of CAD sever-
ity and LVEF in a large international multicenter cohort of
patients undergoing CCTA.
Methods
Centers with prospectively collected CCTA databases (previously
published and unpublished data) using at least 64-slice CT were
invited to contribute to a larger multicenter observational registry.
Qualifying sites contributed baseline demographics, cardiac risk
factors, CCTA findings, and outcomes such as all-cause mortality
and major adverse cardiac events. Between February 2003 and
December 2009, 27 125 consecutive patients underwent CCTA at
12 enrolling centers in 6 countries (Canada, Germany, Italy,
Korea, Switzerland, and the United States) and were prospec-
tively entered into an international multicenter Cardiac CT
Registry (CONFIRM Registry).13 Each enrolling center contrib-
uted 499 to 4912 patients for analysis. CCTA patients with
concomitant CT LVEF assessment were screened for study
analysis. Patients with a history of myocardial infarction, coro-
nary revascularization (coronary artery bypass and/or percutane-
ous coronary intervention), or cardiac transplantation were ex-
cluded from analysis. Follow-up procedures were approved by all
study centers’ institutional review boards.
Clinical Predictors
A medical history was recorded for all patients. Patients’ pretest
probability for obstructive CAD was calculated by using age, sex,
and symptoms,11,14–16 and each patient’s risk of future cardiac event
was estimated using National Cholesterol Education Program-Adult
Treatment Panel (NCEP-ATP) III guidelines.11,17
CCTA Measures: CAD Severity and LVEF
Coronary CT angiography image acquisition and interpretation were
performed as per clinical routine at each participating center.11,18–21
All scanners were single- or dual-source 64-slice CT scanners.
Coronary diameter stenoses were graded using a 4-point score
[normal, mild (50%), moderate (50% to 69%), or severe
(70%)].11,22 Patients were categorized as normal, nonobstructive
CAD, non–high-risk obstructive (50% diameter stenosis) CAD,
and high-risk CAD (defined as having a left main stenosis (50%),
or 3-vessel disease (70%), or 2-vessel disease (70%) involving
the proximal left anterior descending artery).11,23,24 LVEF was
calculated using end-diastole and end-systole volumes and LVEF
50% was considered abnormal.11,25
Patient Follow-Up
Patient follow-up for all-cause mortality was performed by each
local institution by telephone interview, with validation of reported
death through medical records whenever possible and/or a national
death registry.
Statistical Analysis
Statistical analyses were performed using SAS (version 9.2, SAS
Institute Inc, Cary, NC), and statistical significance was defined as
P0.05. Continuous variables were presented as means and standard
deviations, and categorical variables were presented as frequencies
with percentages. To compare patient characteristics, the Wilcoxon
rank sum test was used to compare continuous variables and the 2
test was used for categorical variables.
The prognostic value of CAD severity and LVEF was assessed
for both univariable associations and multivariable associations,
with all-cause mortality using Cox proportional hazard models.
For the risk-adjusted analysis, the independent prognostic value
of LVEF and CAD severity was assessed by controlling for
clinical predictors (NCEP/ATP III) and creating adjusted survival
curves. Model overfitting was considered, and the proportional
hazards assumption was met. The incremental value of LVEF and
CAD severity was calculated by defining the clinical predictor
model followed by the addition of LVEF and CAD severity.
Receiver-operator characteristic curves were constructed for the
models of clinical predictors only, clinicalLVEF, and
clinicalLVEFCAD severity, respectively. The area under the
receiver-operator characteristic curves (95% confidence intervals
[CI]) was compared to evaluate the discrimination ability of
LVEF over clinical predictors and CAD severity over
clinicalLVEF to predict all-cause mortality using the method
proposed by DeLong et al.26 The improvement of reclassification
using CAD severity and LVEF was assessed using a recently
published method that estimated the net reclassification improve-
ment (NRI).27 For calculating the NRI, rescaled individual pre-
dicted risks from models with and without LVEF or with and
without CAD severity were compared with the 10-year NCEP/
ATPIII risk by the observed 4-year event rate.28 This approach
separately analyzed the reclassification of persons who had events
and those who did not have events. Upward movement/improve-
ment in reclassification occurred when patients with death were
appropriately classified into a higher-risk group, and reclassifi-
cation downward occurred when the test failed to identify a
patient with an event. Among patients without death, reclassifi-
cation upward was considered disadvantageous and reclassifica-
tion downward was considered advantageous. Improvement in
reclassification was estimated by taking the sum of differences in
proportions of individuals reclassified upward minus the propor-
tion reclassified downward for patients who had death and the
proportion of individuals moving downward minus the proportion
moving upward for those who did not have death. The statistical
significance of the overall improvement was assessed with an
asymptotic test.
A similar analysis was performed using a subgroup of 7015 CCTA
patients with absolute LVEF measures to evaluate the incremental
value of LVEF as a continuous variable. A secondary analysis was
also performed that included patient symptoms (chest pain and
dyspnea) in the multivariable analysis.
Results
The CONFIRM registry screened 27 125 CCTA patients at
12 participating centers. Of the 15 168 patients with clinical
variables, CAD severity and LVEF assessment (normal
versus abnormal LVEF), 1104 patients were excluded for a
history of coronary revascularization and/or cardiac trans-
plant. Of the 14 064 patients eligible for analysis, 7015
(50.2%) patients had absolute LVEF measurements; 98
(0.70%) patients were lost to follow-up. The final study
population comprised 13 966 (99.3%) patients (mean age,
56.613.2 years; 50.9% men), with a median follow-up of
22.5 months (95% CI, 22.3 to 22.7) (Table 1).
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All-Cause Mortality
At follow-up, all-cause mortality was observed in 271 pa-
tients (1.94%), with an annualized mortality rate for the entire
study cohort of 1.06%. The absence of coronary atheroscle-
rosis conferred an excellent prognosis, with only 38 (0.65%)
deaths and an annual mortality rate of 0.36%. Patients with
nonobstructive CAD had a death rate of 1.99% (n89),
which equates to an annualized mortality rate of 1.14%.
Death occurred in 90 of the 1818 patients (4.95%) with
high-risk CAD compared with 54 (2.90%) of 1861 patients
with non–high-risk CAD. The mean LVEF of patients who
died was lower that of those who survived (54.017.7% and
62.011.4%, respectively). Of the 1887 patients with abnor-
mal LVEF, 87 (4.61%) died compared with 184 (1.52%)
deaths in patients with normal LVEF. Patients with high-risk
CAD had an annual death rate of 2.63% compared with
1.41% in patients with non–high-risk CAD.
Cox Models of Risk-Adjusted Outcomes
In univariate analysis, clinical parameters (age, chest pain,
dyspnea, cardiac risk factors, body mass index, and NCEP/
ATP III) and CT parameters (severity of CAD and abnormal
LVEF) were significant predictors for all-cause mortality
(Table 2). For the risk-adjusted analysis, the NCEP/ATP III







Mean follow-up, mo (95% CI) 22.5 (22.3 to 22.7)
Age, y 56.613.2 56.613.2 50.611.9 0.001
Men 7157 (50.9%) 7104 (50.9%) 53 (54.1%) 0.526
Body mass index, kg/m2† 28.45.8 28.45.8 28.35.8 0.875
Pretest likelihood CAD (%) 32.428.0 35.529.4 24.526.8 0.001
Reason for test
Chest pain 9734 (69.2%) 9669 (69.2%) 65 (66.3%) 0.535
Nonanginal chest pain 4039 (28.7%) 4007 (28.7%) 32 (32.7%) 0.388
Atypical chest pain 3339 (23.7%) 3320 (23.8%) 19 (19.4%) 0.309
Typical chest pain 2356 (16.8%) 2342 (16.8%) 14 (14.3%) 0.512
Dyspnea 1141 (8.1%) 1126 (8.1%) 15 (15.3%) 0.011
Other 2991 (21.3%) 2973 (21.3%) 18 (18.4%) 0.439
Cardiac risk factors
Smoker/ex-smoker 5876 (41.8%) 5822 (41.7%) 54 (55.1%) 0.007
Hypertension 7417 (52.7%) 7381 (52.8%) 36 (38.7%) 0.001
Dyslipidemia 7467 (53.1%) 7418 (53.1%) 49 (50.0%) 0.532
Diabetes 2092 (14.9%) 2083 (14.9%) 9 (9.2%) 0.112
Family history of CAD 6068 (43.1%) 6016 (43.1%) 52 (53.1%) 0.047
CCTA results
Normal coronaries 5857 (41.6%) 5822 (41.7%) 35 (35.7%) 0.232
Nonobstructive CAD (50%) 4508 (32.1%) 4465 (32.0%) 43 (43.9%) 0.012
Obstructive CAD (50%), non–high risk 1878 (13.4%) 1861 (13.3%) 17 (17.3%) 0.243
Obstructive CAD, high-risk CAD 1821 (12.9%) 1818 (13.0%) 3 (3.1%) 0.001
NCEP/ATPIII score
Low 3319 (23.6%) 3291 (21.7%) 28 (28.6%) 0.245
Intermediate 8160 (58.0%) 8110 (59.0%) 50 (51.0%) 0.159
High 2585 (18.4%) 2565 (19.3%) 20 (20.4%) 0.603
Abnormal LVEF, 50% 1895 (13.5%) 1887 (10.8%) 8 (8.2%) 0.122
LVEF‡ 61.811.7 61.811.7 63.010.9 0.315
Radiation exposure, mSv 10.75.7 10.65.7 15.12.9 0.001
CI indicates confidence interval; CAD, coronary artery disease; CCTA, coronary computed tomographic angiography; NCEP/ATP III,
National Cholesterol Education Program/Adult Treatment Panel III; and LVEF, left ventricular ejection fraction.
Values given are meanSD or n (%).
*Comparison of the patients with and without follow-up.
†Body mass index was only measured in 9384 (66.7%) patients (9286 with follow-up and 98 without follow-up).
‡Left ventricular volumes were not measured in 6958 patients, therefore LVEF in the remaining 7106 (50.5%) patients (7015 with
follow-up and 91 patients without follow-up) was used for analysis.
Radiation exposure was only measured in 5010 (35.6%) patients (4919 with follow-up and 91 without follow-up).
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score was used as a clinical predictor to determine the
incremental value of CCTA measures because it combined
age, sex, and cardiac factors into a single measure. A
multivariable Cox model of CAD severity and abnormal
LVEF was tested, and CAD severity and abnormal LVEF
remained independent predictors of all-cause mortality after
adjusting for clinical characteristics (Figures 1 and 2 and
Tables 3 and 4). Patient symptoms were included in a
secondary analysis and showed that chest pain appeared to be
protective (hazard ratio, 0.65; [0.51 to 0.83]) and that dyspnea
did not have independent prognostic value (Table 5). The
addition of symptoms to the Cox models did not alter the
prognostic value of CCTA.
Receiver-operator characteristic curves were created for
clinical predictors and the models with each CCTA mea-
sure, and the area under the curve was compared to assess
the discrimination ability of each additional measure
(Figure 3). The addition of each variable resulted in a
significant improvement in the area under the curve
(P0.001).
Absolute LVEF was available for 7015 (50.2%) patients,
and a subanalysis was performed using LVEF as a continuous
variable. These results also confirmed the independent and
incremental prognostic value of LVEF (Table 5).
Incremental Prognostic Value of CAD Severity
and LVEF
The incremental prognostic value of abnormal LVEF and
CAD severity over clinical predictors was evaluated. The
patient classification was significantly improved when
LVEF was added to a model containing clinical variables
only (NRI, 22.5%; P0.001). A total of 50 (18.5%)
patients who had an event were appropriately reclassified
upward, and a total of 35 (12.9%) patients who had an
event were reclassified downward. Similar calculations for
patients who did not have an event revealed a total of 3248
(23.7%) patients who were correctly reclassified down-
ward and a total of 917 (6.7%) patients who were reclas-
sified upward. Also, when CAD severity was added to a
model containing clinical variables and LVEF, a total of 53







Age, 10-y increase 56.413.1 68.612.7 2.16 (1.95 to 2.39) 0.001
Male 6964 (50.8%) 142 (52.4%) 1.07 (0.84 to 1.35) 0.605
Body mass index, kg/m2 28.45.8 26.56.1 0.93 (0.91 to 0.96) 0.001
Chest pain 9502 (69.4%) 167 (61.6%) 0.67 (0.53 to 0.86) 0.001
Dyspnea 5589 (40.8%) 132 (48.7%) 1.32 (1.04 to 1.68) 0.021
Pretest likelihood for CAD 1.13 (0.89 to 1.42)
Low 3665 (26.7%) 67 (24.7%) 0.315
Intermediate 9366 (68.4%) 184 (67.9%)
High 671 (4.9%) 20 (7.4%)
Cardiac risk factors
Diabetes 2003 (14.6%) 80 (29.5%) 2.36 (1.82 to 3.07) 0.001
Dyslipidemia 7305 (53.3%) 115 (42.3%) 0.64 (0.50 to 0.81) 0.001
Hypertension 7192 (52.5%) 189 (69.7%) 2.05 (1.58 to 2.66) 0.001
Family history of CAD 5920 (43.2%) 96 (35.4%) 0.71 (0.55 to 0.91) 0.007
Smoker/ex-smoker 5684 (41.5%) 141 (52.0%) 1.50 (1.18 to 1.90) 0.001
NCEP/ATPIII risk 2.37 (1.95 to 2.86)
Low 3273 (23.9%) 23 (8.5%) 0.001
Intermediate 7967 (58.1%) 145 (53.5%)
High 2462 (18.0%) 103 (38.0%)
CAD severity 1.76 (1.59 to 1.95)
No CAD 5787 (42.2%) 38 (14.0%) 0.001
Nonobstructive 4380 (32.0%) 89 (32.8%)
Obstructive 1807 (13.2%) 54 (19.9%)
High risk 1728 (12.6%) 90 (33.2%)
Abnormal LVEF 50% 1800 (13.1%) 87 (32.1%) 3.15 (2.44 to 4.07) 0.001
LVEF (10% reduction)* 62.011.4 54.017.7 1.56 (1.42 to 1.72) 0.001
CI indicates confidence interval; CAD, coronary artery disease; NCEP/ATP III, National Cholesterol Education
Program/Adult Treatment Panel III; and LVEF, left ventricular ejection fraction.
*Analysis of left ventricular volumes was performed in 7015 (50.23%) patients (6829 patients with no death and 186
patients with death).
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(19.6%) patients who had an event were reclassified
upward, and a total of 29 (10.7%) patients who had an
event were reclassified downward. For patients who did
not have an event, a total of 2954 (21.6%) patients were
reclassified downward and a total of 1732 (12.6%) patients
were reclassified upward. The CAD severity model yielded
an NRI of 17.8% (P0.001) when added to the model of
clinicalLVEF (Figure 4).
Figure 1. Cox risk-adjusted all-cause mortality-free survival by coronary artery disease (CAD) severity for patients without coronary ath-
erosclerosis (blue line), nonobstructive CAD (green line), non–high-risk CAD (red line), and high-risk CAD (black line); P0.001.
Figure 2. Cox risk-adjusted all-cause mortality-free survival by coronary artery disease (CAD) severity in a subgroup of 7015 patients
with absolute left ventricular ejection fraction measures for patients without coronary atherosclerosis (blue line), nonobstructive CAD
(green line), non–high-risk CAD (red line), and high-risk CAD (black line); P0.001.
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Homogeneity of Results
The homogeneity of the results was evaluated across different
sites. Overall, there is no significant heterogeneity identified.
For the risk-adjusted analysis, CAD severity and abnormal
LVEF remained independent predictors of all-cause mortality
after adjusting for clinical characteristics. The direction of
hazard ratios for CAD severity and abnormal LVEF was
consistent across different sites.
Discussion
In the present analysis of the international multicenter
CONFIRM Registry, we observed an additive prognostic
value of CCTA-measured LVEF and CAD severity for the
prediction of all-cause mortality. Both CAD severity and
abnormal LVEF had incremental prognostic value over base-
line clinical variables alone, and the CAD severity was
incremental to LVEFclinical variables.
Prognostic Value of CCTA
Several single-center studies have examined the prognostic
value of CCTA and the incremental value of LVEF above
CAD severity.6 –11 Our results expand on previous litera-
ture by confirming that measures of CCTA (CAD severity
and abnormal LVEF) have prognostic value in a large
international multicenter registry. The variety of sites
included in the analysis ensures that these measures are
clinically useful across different ethnicities and different
institutions with potentially different CCTA reading
thresholds. Similarly, the different centers used different
CT platforms and postprocessing software, suggesting that
assessments of LVEF and CAD severity were independent
of vendor.
With the increasing use of prospective ECG-triggered
image acquisition to minimize patient radiation exposure,
LVEF may not be routinely available with all CCTA.







NCEP/ATPIII risk 2.36 (1.95 to 2.86) 0.001
ClinicalLVEF 50%
NCEP/ATPIII risk 2.25 (1.86 to 2.73) 0.001
LVEF 50% 2.91 (2.25 to 3.76) 0.001
ClinicalLVEF 50%CAD severity
NCEP/ATPIII risk 1.87 (1.53 to 2.29) 0.001
LVEF 50% 2.72 (2.10 to 3.51) 0.001
CAD severity 1.58 (1.42 to 1.76) 0.001
No CAD 1.0 . . .
Nonobstructive CAD (50%) 2.75 (1.88 to 4.04) 0.001
Obstructive CAD (50%), non–high risk 3.30 (2.17 to 5.04) 0.001
Obstructive CAD, high risk 4.96 (3.36 to 7.31) 0.001
CCTA indicates coronary computed tomographic angiography; CI, confidence
interval; NCEP/ATP III, National Cholesterol Education Program/Adult Treatment
Panel III; LVEF, left ventricular ejection fraction; and CAD, coronary artery
disease.
Table 4. Cox Models of CCTA Measures and All-Cause








NCEP/ATPIII risk 2.37 (1.89 to 2.97) 0.001
ClinicalLVEF
NCEP/ATPIII risk 2.27 (1.81 to 2.85) 0.001
LVEF (10% reduction) 1.52 (1.38 to 1.68) 0.001
ClinicalLVEFCAD
NCEP/ATPIII risk 2.04 (1.61 to 2.59) 0.001
LVEF (10% reduction)* 1.50 (1.36 to 1.65) 0.001
CAD severity 1.31 (1.16 to 1.48) 0.001
No CAD 1.0 . . .
Nonobstructive CAD (50%) 2.57 (1.65 to 4.00) 0.001
Obstructive CAD (50%), non–high risk 2.79 (1.65 to 4.71) 0.001
Obstructive CAD, high risk 2.84 (1.83 to 4.39) 0.001
CCTA indicates coronary computed tomographic angiography; CI, confidence
interval; NCEP/ATP III, National Cholesterol Education Program/Adult Treatment
Panel III; LVEF, left ventricular ejection fraction; and CAD, coronary artery
disease.
*Analysis of left ventricular volumes was performed in 7015 (50.23%)
patients (6829 patients with no death and 186 patients with death).







Clinical variables (including symptoms)
NCEP/ATPIII risk 2.39 (1.97 to 2.89) 0.001
Chest pain 0.65 (0.51 to 0.83) 0.001
Clinical variables (including symptoms)
NCEP/ATPIII risk 2.34 (1.93 to 2.83) 0.001
Chest pain 0.61 (0.47 to 0.78) 0.001
Dyspnea 1.28 (1.00 to 1.64) 0.052
ClinicalLVEF 50%
NCEP/ATPIII risk 2.27 (1.88 to 2.74) 0.001
Chest pain 0.65 (0.51 to 0.84) 0.001
LVEF 50% 2.89 (2.24 to 3.73) 0.001
ClinicalLVEF 50%CAD
NCEP/ATPIII risk 1.88 (1.54 to 2.30) 0.001
Chest pain 0.65 (0.51 to 0.83) 0.001
LVEF 50% 2.71 (2.09 to 3.50) 0.001
CAD severity 1.58 (1.42 to 1.77) 0.001
No CAD 1.0 . . .
Nonobstructive CAD (50%) 2.64 (1.80 to 3.87) 0.001
Obstructive CAD (50%), non–high risk 3.24 (2.12 to 4.94) 0.001
Obstructive CAD, high risk 4.93 (3.35 to 7.27) 0.001
CCTA indicates coronary computed tomographic angiography; CI, confidence
interval; NCEP/ATP III, National Cholesterol Education Program/Adult Treatment
Panel III; LVEF, left ventricular ejection fraction; and CAD, coronary artery
disease.
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However, based on our results, the assessment of LVEF
should be considered if the end-systolic and end-diastolic
datasets are available.
Compared with existing modalities (echocardiography,
radionuclide angiography, and cardiac MRI) commonly
used to assess LVEF, the temporal resolution of contem-
porary multislice CT scanners is suboptimal.2 This limita-
tion may result in the underestimation of end-systolic LV
volumes and potentially the underestimation of LVEF.
However, recent comparisons of LVEF by CCTA to MRI
have shown tight agreement, and our results suggest that
the measurement of LVEF with CT remains of high
clinical value.29 –32 The authors recognize that LVEF as-
sessment is commonly available before CCTA. To ensure
that CAD severity had incremental prognostic value over
LVEF, the sequence of analysis was modified to reflect
this scenario. This new model demonstrated that LVEF had
incremental value over clinical predictors, and the CAD
severity was incremental to LVEF and clinical variables
combined with an NRI of 17.8% (P0.001).
There is mounting enthusiasm for characterization of
coronary atherosclerosis and its potential prognostic value
over CAD severity and LVEF. Because the coronary
calcium scores and plaque characterization were not uni-
formly available for our study cohort, the incremental
values of these measures were not examined.
Prognostic Value of Symptoms
Because patient symptoms may have prognostic value,
chest pain and dyspnea were individually evaluated in the
multivariable analysis. Dyspnea did not have incremental
value over NCEP/ATPIII riskchest pain. Conversely,
chest pain appeared to be protective and was associated
with improved survival. Though this finding appears
counterintuitive, patient symptoms may have biased pa-
tient treatment (medical therapy, revascularization, and
downstream investigations). Importantly, inclusion of
chest pain in the multivariable analysis did not change the
prognostic power of CCTA.
Limitations
All-cause mortality was used as the primary outcome
measure, and the specific causes of death for each patient
were not available. Although a previous study demon-
strated that 41% of all deaths were related to cardiac
causes,11 the proportion of deaths that may have been
attributable to cardiac or cardiovascular events is un-
known. Because the NCEP/ATP III is traditionally used to
predict future cardiovascular events and not all-cause
mortality, the authors recognize the potential limitations of
NCEP/ATP III for predicting all-cause mortality. Such
limitations could result in overestimating the prognostic
value of CCTA. Similarly, the ability of CT measures to
predict cardiac and cardiovascular events (myocardial
infarction and cardiac death) in the COMFIRM Registry
cannot be verified. Body mass index, a potential measure
with prognostic value, was not reported by all centers and
therefore could not be used in the multivariable analysis.
Such exclusion could result in the overestimation of
CCTA’s prognostic value.
The availability of fasting lipid profiles was not uni-
formly available at all centers. For patients with available
fasting lipid profile results, the NCEP was calculated.
Because some patients were already being treated with a
statin, the fasting lipid profile may not represent their true
risk. Because the NCEP/ATP III model was created in a
statin-naive population, patients receiving statin therapy
were presumed to have dyslipidemia and were considered
to have elevated total cholesterol values and normal HDL.
As well, changes in medical therapy as a result of CCTA
results were not documented. However, aggressive risk
factor modification may reduce cardiovascular events,
biasing the results against CCTA.
Not all centers collected information regarding early
revascularization. The authors also recognize that patients
Figure 3. Receiver-operator characteristic
curves show the incremental value of coronary
artery disease (CAD) severity (red line) (area
under the curve [AUC], 0.75; 95% confidence
interval [CI], 0.72 to 0.77; P0.001) over left
ventricular ejection fraction (LVEF) 50%
(blue line) (AUC, 0.68; 95% CI, 0.65 to 0.71;
P0.001) over clinical predictors (black line)
(AUC, 0.64; 95% CI, 0.61 to 0.67).
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diagnosed with obstructive CAD are more likely to un-
dergo revascularization, which may improve patient sur-
vival. This could lead to lower mortality rates in the
cohort, resulting in the underestimation of the true prog-
nostic value of CCTA.
Not all participating centers reported absolute percent
LVEF; thus LVEF could not be analyzed as a continuous
variable for the entire cohort. Because data regarding
“abnormal LVEF” (50%) was available at most centers,
LVEF was analyzed as a categorical variable. However, a
subanalysis of 7015 patients with absolute LVEF measure-
ments confirmed the findings in the larger cohort.
Conclusions
Our results demonstrate that CCTA measures of CAD sever-
ity and LVEF have independent prognostic value. CAD
severity has incremental value over LVEFclinical variables
for predicting all-cause death.
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CLINICAL PERSPECTIVE
The prognostic value of cardiac computed tomographic angiography has been demonstrated in single center studies; however,
large multicenter studies validating the prognostic value of CCTA and LVEF are lacking. Using a large international multicenter
registry (CONFIRM Registry) of 27 125 patients, we sought to confirm the independent and incremental prognostic value of
coronary artery disease (CAD) severity measured using 64-slice CT over left ventricular ejection fraction (LVEF) and clinical
variables. Multivariable analysis of 14 064 patients, confirmed that LVEF 50% (hazard ratio, 2.74 [2.12 to 3.51]) and CAD
severity (hazard ratio, 1.58; 95% confidence interval, 1.42 to 1.76) were predictors of all-cause mortality and CAD severity had
incremental value over LVEF and clinical variables. Our results demonstrate that CCTA measures of CAD severity and LVEF
have independent prognostic value. Incorporation of CAD severity provides incremental value for predicting all-cause death over
routine clinical predictors and LVEF in patients with suspected obstructive CAD.
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